NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

So, this slide should have been distributed out about a year or more ago. Instead, back then, we were given a slide with only the top 1/3 of patients, which was target practice for AF. Now we have a complete slide, except without method A and method B differentiation. That might be in respect for a couple patients who are doing well, even though they received method A. Who knows, but had DCVax-Direct been all method B (aka: four hours less activation time for better results), this chart would have been even more amazing than it is now/below -- much more so, imo. Still, method A really did, imo, act like an active control. Dr. Bosch is right about that. (In the DCVax-L trial, I think that at least the first 2/3 of the first 38 patients enrolled will also act like an active control of sorts.)

Anyway, here again is the DCVax-L survival chart which subtracts expected longevity from the calculus.